Contact this trialFirst, we need to learn more about you.
PI3K Inhibitor
Intermittent Duvelisib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 2
Portland, Oregon
This trial is testing how well duvelisib works on an irregular schedule to treat CLL or SLL. Duvelisib may stop cancer cell growth by blocking some enzymes needed for cell growth. Giving duvelisib on an irregular schedule may reduce severe side effects.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service